The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn’’s disease

By Mascheretti Silvia   Schreiber Stefan  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-09 ,pp. : 479-486

Future Medicine

Access to resources Recommend Favorite

Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects

By  

Drug Design Reviews - Online, Vol. 1, Iss. 2, 2004-01 ,pp. : 111-117

Bentham Science Publishers

Access to resources Recommend Favorite

A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients

By Fu Bo   Lunt Mark   Galloway James   Dixon Will   Hyrich Kimme   Symmons Deborah  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 2, 2013-03 ,pp. : 461-476

Taylor & Francis Ltd

Access to resources Recommend Favorite

Therapy of Crohn’s disease in childhood

By Beattie R Mark   Bremner A Ronald F  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 809-825

Informa Healthcare

Access to resources Recommend Favorite

Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohn's Disease: Tipping the Balance

By  

Current Medicinal Chemistry, Vol. 14, Iss. 14, 2007-01 ,pp. : 1489-1497

Bentham Science Publishers

Access to resources Recommend Favorite